Topic prioritisation

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Prioritisation programme

Prioritisation programme

Decision

Decision

Showing 1 to 10 of 379

TitlePrioritisation programmeDecisionDecision date
Subcutaneous olanzapine for treating schizophrenia [TSID12289]Medicines evaluationNot selected
Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]Medicines evaluationNot selected
Cyclosporin eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]Medicines evaluationNot selected
Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]None selectedNot selected
Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]None selectedAwaiting decision
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]None selectedAwaiting decision
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]None selectedAwaiting decision
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [TSID12287]None selectedAwaiting decision
Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]None selectedNot selected
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]None selectedNot selected

Results per page

  1. 10
  2. 25
  3. 50
  4. All